Optipharm.CO.LTD (153710) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.037x

Based on the latest financial reports, Optipharm.CO.LTD (153710) has a cash flow conversion efficiency ratio of 0.037x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩905.29 Million ≈ $613.51K USD) by net assets (₩24.55 Billion ≈ $16.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 153710 stock market capitalisation for the company's overall valuation and market capitalisation.

Optipharm.CO.LTD - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Optipharm.CO.LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Optipharm.CO.LTD Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Optipharm.CO.LTD ranked by their cash flow conversion efficiency. Explore Optipharm.CO.LTD cash flow quality index to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Halcyon Technology Public Company Limited BK:HTECH	0.022x
Bengang Steel Plates Co Ltd SHE:200761	-0.080x
Whitbread PLC LSE:WTB	0.105x
Genie Music Corporation KQ:043610	0.050x
Ado Optronics TWO:3516	0.009x
Pancontinental Energy NL AU:PCL	-0.064x
Werewolf Therapeutics Inc NASDAQ:HOWL	0.407x
Health In Tech, Inc. Class A Common Stock NASDAQ:HIT	-0.154x

Annual Cash Flow Conversion Efficiency for Optipharm.CO.LTD (2015–2025)

The table below shows the annual cash flow conversion efficiency of Optipharm.CO.LTD from 2015 to 2025. View 153710 share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩25.40 Billion ≈ $17.21 Million	₩-1.55 Billion ≈ $-1.05 Million	-0.061x	-180.98%
2024-12-31	₩27.34 Billion ≈ $18.52 Million	₩-595.50 Million ≈ $-403.56K	-0.022x	+68.20%
2023-12-31	₩25.14 Billion ≈ $17.04 Million	₩-1.72 Billion ≈ $-1.17 Million	-0.069x	+18.34%
2022-12-31	₩29.01 Billion ≈ $19.66 Million	₩-2.43 Billion ≈ $-1.65 Million	-0.084x	-31.87%
2021-12-31	₩30.96 Billion ≈ $20.98 Million	₩-1.97 Billion ≈ $-1.33 Million	-0.064x	-32.95%
2020-12-31	₩33.78 Billion ≈ $22.89 Million	₩-1.62 Billion ≈ $-1.10 Million	-0.048x	-480.82%
2019-12-31	₩35.61 Billion ≈ $24.13 Million	₩447.47 Million ≈ $303.24K	0.013x	-62.99%
2018-12-31	₩35.44 Billion ≈ $24.02 Million	₩1.20 Billion ≈ $815.47K	0.034x	+66.43%
2017-12-31	₩12.79 Billion ≈ $8.67 Million	₩260.86 Million ≈ $176.78K	0.020x	-68.03%
2016-12-31	₩13.50 Billion ≈ $9.15 Million	₩861.36 Million ≈ $583.73K	0.064x	+136.47%
2015-12-31	₩4.30 Billion ≈ $2.91 Million	₩-751.51 Million ≈ $-509.29K	-0.175x	--

About Optipharm.CO.LTD

KQ:153710 Korea Diagnostics & Research

Market Cap

$46.92 Million

₩69.24 Billion KRW

Market Cap Rank

#22227 Global

#1404 in Korea

Share Price

₩4720.00

Change (1 day)

+0.00%

52-Week Range

₩4260.00 - ₩6200.00

All Time High

₩28900.00